About Araceli Biosciences
Araceli Biosciences builds high-content imaging hardware and AI-driven analysis software for drug discovery. Its Endeavor systems image cells at high throughput, and the Clairvoyance software analyzes the results in real time. The flagship Endeavor system can produce results up to 40 times faster than traditional imaging systems. Pharmaceutical and biotech laboratories use the Endeavor systems to screen compounds and generate data for AI-driven discovery pipelines.
The company is based in the Portland, Oregon area, with offices at 7405 SW Tech Center Drive in Tigard, Oregon. It closed an $11.2 million seed financing round in April 2025, bringing total funding since spinning out of Phoseon Technology to that amount. Matt Beaudet is president and chief executive officer, and Shawn MacDonald is chief financial officer.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 20, 2026 | Nov 3, 2026 | $2,526,065of $4.5M target | 4 | $631K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Dec 31, 2024 | Jan 15, 2025amended Dec 9, 2025 | $12,236,994of $14.0M target | 28 | $437K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Apr 11, 2023 | Apr 26, 2023 | $2,225,000of $4.0M target | 3 | $741K | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, three offerings | $16,988,059 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Araceli Biosciences
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Apr 24, 2025 | Seed | $11.2 million | Bill Cortelyou (lead) | Press release ↗ |
Why Investors Backed Araceli Biosciences
Araceli Biosciences sells high-content imaging systems and AI-driven analysis software to drug discovery labs. Araceli's case is that slow imaging and analysis create a bottleneck that keeps researchers from making fast, data-driven decisions. The company closed an $11.2 million seed round in April 2025, adding to funds raised since its spinout from Phoseon Technology. It has since appointed a new board director and expanded its reach into Europe.
The problem it targets
Drug discovery teams need large amounts of cellular data to screen compounds and select promising candidates. Araceli says traditional high-content imaging systems are too slow for AI-driven pipelines and multiplexed assays. It calls imaging one of the slowest steps in drug discovery.
What the product does
The Endeavor system images cells at high throughput and feeds the results into Clairvoyance, Araceli's AI-driven analysis software, to give researchers real-time, actionable data. The newer Endeavor Live Cell version adds kinetic imaging, capturing roughly four-minute timepoints across full 1536-well plates so scientists can track living cells as they change over an experiment.
Progress so far
Araceli has launched new products and formed partnerships since it first brought its Endeavor platform to market. It built Endeavor Live Cell with Okolab, entered Ginkgo Bioworks' Nebula Lab-in-the-Loop program, and began a collaboration with Viqi on AI-driven phenotypic profiling. VALID Therapeutics has also partnered with Araceli to apply its platform to drug discovery. The company appointed Matt Beaudet as president and chief executive officer in 2024 and added Christine Tsingos to its board in 2026.
Who backs it
Bill Cortelyou, Araceli's board chairman, was the lead investor in its April 2025 seed round. He said Araceli's technology, experienced leadership, and market demand position the company for growth. The company announced in 2026 that it had added Christine Tsingos to its board.
We wrote this summary from public statements by Araceli Biosciences and its investors. It is not investment advice.
Araceli Biosciences in the News
Leadership Team
Executive officers and directors listed on Araceli Biosciences's Form D filed Nov 3, 2026.
Earlier filings also listed Kevin Gabelein (director, last listed Dec 2025), Scott Igl (executive officer, last listed Apr 2023) and Jeff Harris (executive officer, last listed Apr 2023).